X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (210) 210
Publication (36) 36
Book / eBook (9) 9
Book Review (7) 7
Book Chapter (4) 4
Conference Proceeding (4) 4
Newspaper Article (3) 3
Patent (2) 2
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (69) 69
index medicus (63) 63
male (62) 62
female (48) 48
middle aged (45) 45
aged (33) 33
animals (33) 33
adult (30) 30
neuroendocrine tumors (28) 28
oncology (27) 27
tumors (25) 25
article (19) 19
physiology (19) 19
aged, 80 and over (18) 18
metastasis (18) 18
cancer (17) 17
survival (17) 17
cardiac & cardiovascular systems (16) 16
treatment outcome (16) 16
neuroendocrine tumors - drug therapy (15) 15
patients (15) 15
peripheral vascular disease (14) 14
antineoplastic agents - therapeutic use (13) 13
medical and health sciences (13) 13
medicin och hälsovetenskap (13) 13
rats (13) 13
superoxides - metabolism (13) 13
disease-free survival (12) 12
everolimus (12) 12
neuroendocrine tumors - pathology (12) 12
antineoplastic agents - adverse effects (11) 11
double-blind method (11) 11
somatostatin - analogs & derivatives (11) 11
abridged index medicus (10) 10
chemotherapy (10) 10
clinical medicine (10) 10
klinisk medicin (10) 10
medicine, general & internal (10) 10
octreotide (10) 10
oxidative stress (10) 10
analysis (9) 9
cattle (9) 9
gastroenterology & hepatology (9) 9
in vitro techniques (9) 9
management (9) 9
prognosis (9) 9
quality of life (9) 9
cancer and oncology (8) 8
cancer och onkologi (8) 8
cancer therapies (8) 8
care and treatment (8) 8
endocrinology & metabolism (8) 8
enzyme inhibitors - pharmacology (8) 8
expression (8) 8
medicine & public health (8) 8
neoplasms (8) 8
neuroendocrine tumors - mortality (8) 8
obesity (8) 8
pancreatic neoplasms - drug therapy (8) 8
pancreatic neoplasms - pathology (8) 8
pharmacology & pharmacy (8) 8
prognostic-factors (8) 8
research (8) 8
respiratory system (8) 8
united-states (8) 8
young adult (8) 8
acetylcholine - pharmacology (7) 7
adolescent (7) 7
carcinoid-tumors (7) 7
diagnosis (7) 7
disease progression (7) 7
dose-response relationship, drug (7) 7
gastroenterology and hepatology (7) 7
guidelines (7) 7
internal medicine (7) 7
kaplan-meier estimate (7) 7
nadh oxidase (7) 7
nitric oxide - metabolism (7) 7
octreotide - therapeutic use (7) 7
risk factors (7) 7
somatostatin (7) 7
somatostatin - therapeutic use (7) 7
studies (7) 7
surgery (7) 7
time factors (7) 7
united states (7) 7
bradykinin - pharmacology (6) 6
carcinoid tumor - drug therapy (6) 6
consensus guidelines (6) 6
delayed-action preparations (6) 6
epidemiology (6) 6
exercise (6) 6
gastrointestinal neoplasms - drug therapy (6) 6
medical prognosis (6) 6
medical research (6) 6
metastases (6) 6
neuroendocrine tumors - therapy (6) 6
progression-free survival (6) 6
public, environmental & occupational health (6) 6
retrospective studies (6) 6
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
UTL at Downsview - May be requested (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gardiner Museum - Library use only (1) 1
Law (Bora Laskin) - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Thomas Fisher Rare Book - May be requested at Fisher (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the History of Ideas, ISSN 0022-5037, 2016, Volume 77, Issue 1, pp. 99 - 106
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10022, pp. 968 - 977
Journal Article
Cancer Letters, ISSN 0304-3835, 2013, Volume 335, Issue 1, pp. 1 - 8
Highlights ► Dysregulation of the PI3K/Akt/mTOR pathway can occur at multiple nodes in pNETs, providing several potential drug targets. ► PI3K pathway... 
Hematology, Oncology and Palliative Medicine | mTOR | Inhibitor | Akt | PI3K | Pancreatic | Neuroendocrine tumors | MTOR | MAMMALIAN TARGET | PROTEIN-KINASE-C | ISLET-CELL CARCINOMA | MTOR PATHWAY | ENDOCRINE TUMORS | REVEALS ALTERATIONS | RAD001 EVEROLIMUS | GROWTH-FACTOR RECEPTOR | AKT INHIBITION | ONCOLOGY | LOW-GRADE | Sirolimus - analogs & derivatives | Signal Transduction | TOR Serine-Threonine Kinases - metabolism | Humans | Pancreatic Neoplasms - enzymology | Clinical Trials as Topic | Phosphatidylinositol 3-Kinases - metabolism | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Neuroendocrine Tumors - enzymology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pancreatic Neoplasms - drug therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroendocrine Tumors - drug therapy | Proto-Oncogene Proteins c-akt - metabolism | Everolimus | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Proteins | Studies | Epidermal growth factor | Disease | Pathogenesis | Insulin-like growth factors | Tumorigenesis | Metastasis | Kinases | Gene expression | Vascular endothelial growth factor | Tumors
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9808, pp. 2005 - 2012
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. e435 - e446
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 224 - 233
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 6, pp. 514 - 523
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 09/2015, Volume 9, pp. 5075 - 5086
In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable... 
Somatostatin analogues | Pasireotide | Symptom control | Progression-free survival | Carcinoid syndrome | Neuroendocrine tumors | CONSENSUS GUIDELINES | SOM230 | CHEMISTRY, MEDICINAL | MANAGEMENT | pasireotide | symptom control | progression-free survival | PHARMACOLOGY & PHARMACY | carcinoid syndrome | somatostatin analogues | neuroendocrine tumors | Digestive System Neoplasms - mortality | Somatostatin - adverse effects | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Digestive System Neoplasms - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Digestive System Neoplasms - pathology | Aged, 80 and over | Adult | Female | Odds Ratio | Somatostatin - analogs & derivatives | Double-Blind Method | Carcinoid Tumor - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Octreotide - adverse effects | Logistic Models | Treatment Outcome | Tumor Burden | Octreotide - therapeutic use | Carcinoid Tumor - secondary | Disease-Free Survival | Aged | Somatostatin - therapeutic use | Carcinoid Tumor - mortality | Drug Substitution | Delayed-Action Preparations | Controlled release technology | Testing | Signs and symptoms | Statistical analysis | Diarrhea | Oncology | Octreotide | Nausea | Metastasis | Cancer therapies | Patients | Metastases | Confidence intervals | Refractory materials | Hyperglycemia | Hospitals | Intestine | Diabetes | Somatostatin | Digestive tract | Drug dosages | Predictive control | Tumors | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cancer and Oncology | Klinisk medicin | Cancer och onkologi
Journal Article